for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Resverlogix Corp.

RVX.TO

Latest Trade

1.46CAD

Change

-0.02(-1.35%)

Volume

118,198

Today's Range

1.33

 - 

1.54

52 Week Range

0.35

 - 

4.94

As of on the Toronto Stock Exchange ∙ Minimum 15 minute delay

Pricing

Previous Close
1.48
Open
1.54
Volume
118,198
3M AVG Volume
4.02
Today's High
1.54
Today's Low
1.33
52 Week High
4.94
52 Week Low
0.35
Shares Out (MIL)
209.42
Market Cap (MIL)
309.94
Forward P/E
-4.25
Dividend (Yield %)
--

Next Event

Resverlogix Corp at Biotechnology Industry Organization (BIO) Investor Forum Conference

Latest Developments

More

Resverlogix Announces Topline Results In Betonmace Phase 3 Epigenetics Trial

Resverlogix Provides Update On Betonmace Phase 3 Trial

Eastern Capital Exercised Warrants To Acquire 5 Mln Shares Of Resverlogix At Cash Price Of C$0.75/Share, For Total Consideration Of C$3.75 Mln

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Resverlogix Corp.

Resverlogix Corp is Canada-based clinical-stage biotechnology company. The Company is developing apabetalone (RVX-208), a molecule that is a selective bromodomain and extra-terminal (BET) inhibitor. BET bromodomain inhibition is an epigenetic mechanism that can regulate disease-causing genes. Apabetalone is the BET inhibitor selective for the second bromodomain (BD2) within the BET protein called BRD4. This selective inhibition of apabetalone on BD2 produces a specific set of biological effects for patients with high-risk cardiovascular disease (CVD), diabetes mellitus (DM), chronic kidney disease, dialysis, Alzheimer's disease, Fabry disease, other orphan diseases, and peripheral artery disease. Apabetalone is being studied in a Phase III trial, BETonMACE, in high-risk CVD patients with type 2 DM and low high-density lipoprotein (HDL).

Industry

Biotechnology & Drugs

Contact Info

300-4820 Richard Rd SW

+1.403.2549252

https://www.resverlogix.com/

Executive Leadership

Donald J. McCaffrey

Chairman of the Board, President, Chief Executive Officer, Secretary

A. Brad Cann

Chief Financial Officer

Jan O. Johansson

Senior Vice President - Medical Affairs

Kenneth Lebioda

Senior Vice President - Business & Corporate Development

Michael T. Sweeney

Senior Vice President - Clinical Development

Key Stats

2.00 mean rating - 1 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2019

0.0K

2020(E)

0.0K
EPS (USD)

2018

-0.420

2019

-0.900

2020(E)

-0.265
Price To Earnings (TTM)
--
Price To Sales (TTM)
--
Price To Book (MRQ)
--
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
--
LT Debt To Equity (MRQ)
--
Return on Investment (TTM)
--
Return on Equity (TTM)
-639.14

Latest News

Latest News

BRIEF-Resverlogix Advances Us$30 Million Loan Closing Documentation

* RESVERLOGIX ADVANCES US$30 MILLION LOAN CLOSING DOCUMENTATION

BRIEF-Resverlogix Announces Proposed Offering Of Units

* RESVERLOGIX - OFFERING'S PROCEEDS TO FUND RESEARCH & DEVELOPMENT OF CLINICAL TRIAL ACTIVITIES RELATED TO PHASE 3 BETONMACE TRIAL, AMONG OTHERS Source text for Eikon: Further company coverage:

BRIEF-Resverlogix Corp Announces TSX Review Update

* DAY EXTENSION TO NO LATER THAN MAY 14, 2018 FOR TSX'S REVIEW OF CO'S COMPLIANCE WITH ALL OF TSX LISTING REQUIREMENTS Source text for Eikon: Further company coverage:

BRIEF-Resverlogix Says Accepted Commitment Letter For $30 Mln Senior Secured Loan

* RESVERLOGIX CORP - ACCEPTED A COMMITMENT LETTER FOR A US$30 MLN SENIOR SECURED LOAN WITH THIRD EYE CAPITAL Source text for Eikon: Further company coverage:

BRIEF-Resverlogix Exceeds Full Enrollment For The Pivotal Phase 3 Betonmace Clinical Trial

* RESVERLOGIX EXCEEDS FULL ENROLLMENT FOR THE PIVOTAL PHASE 3 BETONMACE CLINICAL TRIAL

BRIEF-Resverlogix Announces Recommendation From Data Safety Monitoring Board For Study Of Apabetalone

* RESVERLOGIX ANNOUNCES SIXTH POSITIVE RECOMMENDATION FROM DATA SAFETY MONITORING BOARD FOR PHASE 3 STUDY OF APABETALONE

BRIEF-Resverlogix Receives FDA Protocol Acceptance For Ongoing Phase 3 Betonmace Trial

* RESVERLOGIX RECEIVES FDA PROTOCOL ACCEPTANCE FOR THE ONGOING PHASE 3 BETONMACE TRIAL

BRIEF-Resverlogix, Medison Pharma Ltd Announce Strategic Licensing Agreement

* RESVERLOGIX AND MEDISON PHARMA LTD. ANNOUNCE STRATEGIC LICENSING AGREEMENT

BRIEF-Resverlogix announces fifth positive recommendation from Data Safety Monitoring Board for Apabetalone

* Resverlogix announces fifth positive recommendation from Data Safety Monitoring Board for phase 3 study of Apabetalone

BRIEF-Resverlogix Corp‍ entered into a Right of First Refusal Agreement with Hepalink USA Inc​

* Resverlogix Corp - entered into a Right of First Refusal Agreement with Hepalink USA Inc

BRIEF-Resverlogix reports $87 mln private placement with Shenzhen Hepalink

* Resverlogix announces $87 million private placement with shenzhen hepalink

BRIEF-Shenzhen Hepalink Pharmaceutical to invest in Canada's Resverlogix Corp

* Says it plans to invest up to C$87 million ($69.75 million) in Canada's Resverlogix Corp

BRIEF-Resverlogix closes extension of maturity date of loan and announces private placement

* Resverlogix closes extension of maturity date of loan and announces private placement

BRIEF-Successful CANTOS Inflammation Trial supports rationale for Resverlogix' ongoing betonmace trial

* under CANTOS trial treatment with Resverlogix' apabetalone has demonstrated a reduction in inflammatory mediator il-6 by 29 percent Source text for Eikon: Further company coverage:

BRIEF-Resverlogix announces extension of maturity date of loan and expression of interest on strategic transaction

* Resverlogix announces extension of maturity date of loan and expression of interest regarding strategic transaction

BRIEF-Resverlogix receives approval pathway from the FDA as to the inclusion of USA patients in the phase 3 betonmace trial

* Resverlogix receives approval pathway from the FDA as to the inclusion of usa patients in the phase 3 betonmace trial

BRIEF-Resverlogix randomizes first patient in Taiwan portion of Betonmace clinical trial

* Resverlogix randomizes first patient in Taiwan/China portion of the phase 3 Betonmace clinical trial

BRIEF-Resverlogix announces fourth positive recommendation from DSMB

* Resverlogix announces fourth positive recommendation from data safety monitoring board for phase 3 study of apabetalone

BRIEF-Eastern Capital Ltd acquires additional shares and warrants of Resverlogix Corp

* Eastern Capital Limited acquires additional shares and warrants of Resverlogix Corp

BRIEF-Resverlogix closed offering, issuing a total of $10 million of equity units

* Closed its previously-announced offering, issuing a total of $10 million of its equity units Source text for Eikon: Further company coverage:

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up